New hope for hard-to-treat lung cancer: drug combo aims to shrink tumors

NCT ID NCT05020769

Ongoing Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug (SI-B001) combined with a standard pill (osimertinib) in people with advanced non-small cell lung cancer that has stopped responding to previous therapies. About 14 adults will receive the combination to see if it can shrink tumors and control the disease. The goal is to find a better treatment option for this tough-to-treat cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL-CELL LUNG CANCER

Contacts and locations

Show contact details

Locations

Sun Yat-sen University Cancer Center (SYSUCC)

Guangdong, Guangzhou, 510075, China
The Second Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China
The Second Affiliated Hospital of Guilin Medical University

Guilin, Guangxi, China